• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

FDA clears Dexcom Partner Web APIs

July 15, 2021 By Sean Whooley

Dexcom updated logoDexcom (NSDQ:DXCM) announced today that it received FDA clearance for its Dexcom Partner Web application programming interfaces (APIs).

The San Diego-based company’s Dexcom Partner Web APIs enable invited third-party developers to integrate real-time continuous glucose monitoring (CGM) data into their digital health apps and devices.

Dexcom’s CGM data can be integrated into third-party apps and devices in several ways, allowing users to quickly see all their therapy data in one place and empower them to use the apps they find most beneficial for a more tailored experience.

The platform also enables in-the-moment diabetes management coaching and feedback.

“FDA clearance of our real-time APIs further solidifies Dexcom as the leader in interoperable CGM, giving Dexcom users even more choice in how they view and interact with their glucose data,” Dexcom chief technology officer Jake Leach said in a news release. “The new APIs will help seamlessly integrate the power of real-time Dexcom CGM data into some of the leading diabetes and digital health solutions.”

According to the release, a number of prominent diabetes and digital health companies have received invitations to access the real-time APIs and are currently in the testing and development phase, including Garmin and Teladoc’s Livongo for Diabetes.

“Garmin welcomes the opportunity to bring Dexcom CGM data to runners, cyclists and everyday users who rely on the technology 24/7 to proactively manage their diabetes,” Garmin VP of fitness Joe Schrick said. “We are proud to be part of this integration that will allow users a secondary way to quickly and discreetly view estimated glucose levels and trends right from their smartwatch at any time.”

Filed Under: Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Patient Monitoring, Technology Tagged With: Dexcom, FDA

IN CASE YOU MISSED IT

  • Medtronic to invest $50M in India Diabetes center
  • Flat Medical partners with Mercury Medical on smart syringe distribution
  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS